In the Review “The immunology of brain tumors” by L. Bunse et al., the following corrections have been made. The term “oncostatin M” has been replaced with “osteopontin” in the sentence “Endothelial cells of the glioma vasculature provide signals to the perivascular niche, such as osteopontin, to induce differentiation of recruited monocytes into TAMs (97).” The term “prevented” has been replaced with “achieved” in the sentence “Enhanced killing and prevention of exhaustion through tonic signaling can also be achieved by introducing a synthetic receptor (SynNotch) recognizing a specific priming antigen (126).” Several references that were previously omitted have been added (7, 47, 48, 64, 129). The sentence “Recent clinical trials have explored the intra-cerebroventricular delivery of bivalent CAR T cells targeting multiple glioblastoma antigens, such as EGFR and IL13Rα2, aiming to overcome antigen heterogeneity and reduce tumor escape” incorrectly cited a reference [(119) in the previous version]. The correct citation [(123) in the current version] is now listed. In Table 1, the primary outcomes of several trials were incorrectly listed as “Not yet reported.” For NCT04185038, NCT04099797, NCT02960230, and NCT05168423, the primary outcome has been corrected to “Positive.”
Erratum for the Review “The immunology of brain tumors” by L. Bunse et al. | Science Immunology
